Pregabalin Capsule
Product Images NDC 71610-792

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71610-792). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 25 mg (71610 0792 30)

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Equation (Pregabain Gault Equation)

This text appears to be a formula for calculating an estimated creatinine clearance value (CLCr) in a patient. It takes into account the patient's age, weight, and serum creatinine level. The formula for male patients is CLCr = 1140 - age (years) x weight (kg), while for female patients it is CLCr = (1140 - age (years) x weight (kg)) x 0.85.*

FDA Label Image

Fig-01 (Pregabalin Figure 01)

FDA Label Image

Fig-02 (Pregabalin Figure 02)

This text appears to be a graph or chart showing the percent improvement in pain from baseline for patients who took either Pregabalin 100 mg three times a day or Placebo. The graph shows percentages ranging from 10% to 100% for the improvement in pain.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

This text appears to be presenting a chart or table showing the percent of patients who have experienced improvement from different doses of pregabalin medication, as well as a placebo. The chart displays four different dosage options: 300 mg twice a day, 150 mg twice a day, 75 mg twice a day, and a placebo. The percentages are listed in increments of 10, from 0% to 100%, indicating the percent improvement in pain from a baseline measurement.*

FDA Label Image

Fig-04 (Pregabalin Figure 04)

FDA Label Image

Fig-05 (Pregabalin Figure 05)

FDA Label Image

Fig-06 (Pregabalin Figure 06)

FDA Label Image

Fig-07 (Pregabalin Figure 07)

FDA Label Image

Fig-09 (Pregabalin Figure 09)

This text appears to be describing the percentage of patients who have experienced improvement in their condition, specifically related to pain. It suggests different daily doses of pregabalin (600 mg, 450 mg, and 300 mg) and a placebo were given to the patients. The text also lists percentages ranging from 20% to 100% to represent the level of improvement in pain from a baseline measurement.*

FDA Label Image

Fig-10 (Pregabalin Figure 10)

This text appears to be a table showing the estimated percentage of subjects without LIR (likely to refer to a medical condition or side effect) for different treatment groups. The treatment groups mentioned are "Pregabalin" and "Placebo". The table also includes a timeline in days, ranging from 80 to 180. However, without clear context or additional information, it is difficult to provide a more specific description.*

FDA Label Image

Fig-11 (Pregabalin Figure 11)

FDA Label Image

Fig-12 (Pregabalin Figure 12)

FDA Label Image

Str (Pregabalin Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.